When will the FDA reclassify BPC-157 to Category 1?
As of Tue, 20 Oct 2026 11:22:28 UTC, Kalshi traders price Before 2027 (30.0%), Before November (14.0%). The market has $111K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Before 2027 | 30.0% | 30.0¢ | 70.0¢ |
| Before November | 14.0% | 14.0¢ | 86.0¢ |
Market details
- Venue: Kalshi
- Volume: $111K
- Liquidity: $111K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for Before 2027:
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes. The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
Sources
Related markets
- Will the U.S. confirm that aliens exist?
- Best AI at the end of 2026?
- When will Anthropic release Mythos?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Measles cases this year?
- Which AI company will have the best coding model at the end of 2026?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.